Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (1542)	4/19/1998 9:52:00 PM
From: scaram(o)uche	Read Replies (3) \| Respond to of 1762

Maurice: The critical observations with dendritic cells were made some time ago. There's no question that they'll be useful for vaccination, but 99% of the antigens being used for tumor studies are KRRRRRR*P. Anti-ids for NHL, however...... I think you could make it work. Unfortunately, the treatment would have to evolve with the tumor (you'd need to keep fighting the somatic variants), and the cost may turn out to be prohibitive. Again, a patient-specific therapy is tough enough, even when the only variable would be the autologous dendritic cells. It would be tougher yet when there are two variants, the easy one (the DC) and the tough one (the id). See Nair et al., Nature Biotechnology 16: 364, 1998. They combine DC with a naked DNA-like concept (transfection with RNA..... if Miljenko is reading this, the RNA codes for CEA). Gotta go! Kids begging for dinner. Cheers! Rick